Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
cfn media  clinical  company  hosted xtalks  marketwired oct  marketwired october  marketwired  media  new  oct  october  webinar 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Thu, 19 Oct 2017 14:50:28 EDT

Copyright: Copyright: (C) Marketwired
 



Synthego Receives Intel Capital Investment to Advance CRISPR Bioinformatics

Thu, 19 Oct 2017 14:17:00 EDT

Growth in genomics and genome engineering requires advanced tools for big data




UPDATE - HempAmericana, Inc. (OTC PINK: HMPQ) Filed its Financial Statements This Week for the Quarter Ending August 31, 2017

Thu, 19 Oct 2017 13:05:58 EDT

NEW YORK, NY--(Marketwired - Oct 19, 2017) - HempAmericana, Inc. (OTC PINK: HMPQ) filed its financial statements this week for the quarter ending August 31, 2017. The company achieved many milestones during the quarter. It raised $320,000 from its Regulation A offering, placed a down payment on a 200-liter extraction machine (lease to own), and formed Hempwerk, Inc., the conduit for its Maine operations. Subsequent to the quarter's end, HMPQ raised an additional $200,000 from the Regulation A offering. As the company continues to seek expansion, it is still actively courting investors for its Regulation A offering, set to expire at the end of March 2018. The company also recently visited a pilot hemp farm in Goshen, NY as it hopes to eventually set up operations in New York State and is actively exploring opportunities for industrial hemp production and products.




HempAmericana, Inc. (OTC PINK: HMPQ) Filed its Financial Statements This Week for the Quarter Ending August 31, 2017

Thu, 19 Oct 2017 11:16:55 EDT

NEW YORK, NY--(Marketwired - Oct 19, 2017) - HempAmericana, Inc. (OTC PINK: HMPQ) filed its financial statements this week for the quarter ending August 31, 2017. The company achieved many milestones during the quarter. It raised $320,000 from its Regulation A offering, placed a down payment on a 200-liter extraction machine (lease to own), and formed Hempwerk, Inc., the conduit for its Maine operations. Subsequent to the quarter's end, HMPQ raised an additional $200,000 from the Regulation A offering. As the company continues to seek expansion, it is still actively courting investors for its Regulation A offering, set to expire at the end of March 2018. The company also recently visited a pilot hemp farm in Goshen, NY as it hopes to eventually set up operations in New York State and is actively exploring opportunities for industrial hemp production and products.




Dewmar Invests in Opportunities within $2.2 Trillion Entertainment Industry, Plus Exclusive CEO Interview -- CFN Media

Thu, 19 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Dewmar International BMC Inc.'s (OTC PINK: DEWM) investments in cannabis-related entertainment projects. CFN Media also interviews the company's CEO, Dr. Marco Moran, about the company's variety of business initiatives in the cannabis, hemp, health, consumer products and entertainment industries.




mCig to Spin-Off Technology Division as a Stand-Alone Public Company

Thu, 19 Oct 2017 08:30:00 EDT

LAS VEGAS, NV--(Marketwired - Oct 19, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis markets, announced today that the company will spin-off its technology division as a stand-alone public company. In conjunction with the spin-off, mCig shareholders will be awarded shares in the proposed public entity based on their holdings in MCIG. mCig Inc. expects to file the appropriate documents with the SEC within the next 45 days. 




Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Thu, 19 Oct 2017 07:49:17 EDT

Pancreatic Proenzymes Provides For Potent Anti-Tumor Efficacy in Pancreatic and Ovarian Cancers




BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia

Thu, 19 Oct 2017 07:30:00 EDT

ANAHEIM, CA--(Marketwired - Oct 19, 2017) - BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2017 Annual Conference at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on October 21-24th.




Preparing for Phase II: Finding the Right Dose, Schedule, and Combination from your Phase I/II Oncology Clinical Trial, New Webinar Hosted by Xtalks

Thu, 19 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 19, 2017) - In a complimentary webinar, experts from Premier Research Paul Hallenbeck, Ph.D., Executive Director of Strategic Development, Oncology, Peter Larson, M.D., Senior Medical Director of Hematology-Oncology and Gabriele Accetta, Principal Biostatistician discuss important factors for planning and executing early-phase oncology clinical trials in preparation for a decision-making Phase II trial. The live event takes place on Tuesday, November 7, 2017 at 11am EST (4pm GMT).




Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

Thu, 19 Oct 2017 07:00:00 EDT

Proprietary cannabinoid drug formulations have now been shown to effectively treat preclinical models of Crohn's disease and ulcerative colitis




Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy

Thu, 19 Oct 2017 06:30:00 EDT

Dynavax Expands its TLR9 Agonist Platform in Combination with Anti-PD-1 Therapy to a Third Tumor Type




Pressure BioSciences and Phasex Announce Strategic Collaboration Addressing Broad Markets for Stable, Water-Soluble Nanoemulsions

Wed, 18 Oct 2017 09:22:37 EDT

Companies Will Combine PBI's Recently Patented Ultra Shear Technology with Phasex's Supercritical Fluid Processing Methods to Enable Development of Stable, Water-Soluble Nanoemulsions, Including CBD-Enriched Plant Oil




Advantis Corp. Finalizes Oregon Contract, Accepts Bitcoin From Some New Customers

Wed, 18 Oct 2017 09:20:00 EDT

NEWPORT BEACH, CA--(Marketwired - Oct 18, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) finalized the deal with a private cannabis grower in Oregon to supply Amster-Can canning and branding services. Advantis is shipping the original canning equipment to Oregon to fulfill orders at full production capacity. As Advantis grows its client base, it has decided to accept Bitcoin as payment from clients that prefer this mode of payment.




Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial

Wed, 18 Oct 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - October 18, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that 14 qualified cancer clinics have requested to participate in its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML").




Simple and Cost-effective Ways to Engage Patients Using eCOA and IRT Systems, New Webinar Hosted by Xtalks

Wed, 18 Oct 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - October 18, 2017) - This webinar will focus on how sponsors and CROs can use IRT and eCOA systems to promote patient engagement through features which reinforce compliance and retention, as well as functionality that allows for sharing information with patients throughout a clinical trial.




Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement

Wed, 18 Oct 2017 07:00:00 EDT

Funds to support continued clinical development of COTI-2 in head and neck squamous cell carcinoma




Building Smart Biomedical Devices Using Glass, Lasers, Sensors, and Chips - New Webinar Hosted by Xtalks

Wed, 18 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 18, 2017) - This webinar will explain how Glass Core Technology will lead customers to new products with a higher level of integration and more innovative features that result in smart biomedical devices and other emerging technologies. The live broadcast takes place on Friday, November 3, 2017 at 11am EDT (3pm GMT), with featured speaker Steve Groothuis, Chief Technology Officer for Samtec Microelectronics.




Orgenesis to Present at BIO Investor Forum

Wed, 18 Oct 2017 06:00:00 EDT

GERMANTOWN, MD--(Marketwired - Oct 18, 2017) - Orgenesis Inc., (OTCQB: ORGS) ("Orgenesis " or "the Company"), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today announced that it will present at the BIO Investor Forum being held October 17-18, 2017 in San Francisco, CA.




The Journey from Passive to Active TMF with C.R. Bard, Inc. and Daiichi Sankyo, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 13:04:48 EDT

As the industry move to eTMF continues at a pace, hear from two organizations about their journeys to optimize clinical trial processes and the benefits they are seeing from making the shift to active TMF




The Hydropothecary Corporation Engages CFN Media to Develop New Investor Audience

Tue, 17 Oct 2017 09:30:00 EDT

SEATTLE, WA--(Marketwired - Oct 17, 2017) - CFN Media Group ("CFN Media", "CannabisFN"), the leading agency and digital media network dedicated to the North American cannabis industry, today announced that The Hydropothecary Corporation (TSX VENTURE: THCX) has engaged CFN Media to conduct a 3-month investor and market visibility program beginning on October 16th, 2017.




Dr. Martin Brenner Joins Recursion to Accelerate an Ambitious Plan to Industrialize Drug Discovery

Tue, 17 Oct 2017 09:00:00 EDT

The Industry Veteran Drug Hunter Brings more than a Decade of Experience to Recursion as Chief Scientific Officer




Abattis Offers a Solution to Canada's Cannabis Pesticide Problem -- CFN Media

Tue, 17 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 17, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF), whose wholly-owned subsidiary is one of the only publicly-traded third-party cannabis testing laboratories. A steady stream of cannabis recalls has prompted regulators in Canada to call for the mandatory testing of cannabis for unauthorized pesticides. With only a handful of third-party laboratories licensed to test cannabis, these service providers are becoming increasingly important.




Aphria Inc. Announces $80 Million Bought Deal

Tue, 17 Oct 2017 08:24:05 EDT

LEAMINGTON, ONTARIO--(Marketwired - Oct. 17, 2017) -




The Journey from Passive to Active TMF with C.R. Bard, Inc. and Daiichi Sankyo, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 07:30:00 EDT

As the industry move to eTMF continues at a pace, hear from two organizations about their journeys to optimize clinical trial processes and the benefits they are seeing from making the shift to active TMF




BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction

Tue, 17 Oct 2017 07:00:00 EDT

ANAHEIM, CA--(Marketwired - Oct 17, 2017) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, President & CEO of BioCorRx, appeared as a guest on MichaeLA hosted by Michaela Pereira live from CNN's Los Angeles bureau, to discuss alcohol addiction and the BioCorRx® Recovery Program, which works to help people suffering from alcohol and opioid abuse disorders. The segment can be viewed in the News & Media section of the BioCorRx website. To find out more information on the BioCorRx Recovery Program please visit www.beataddiction.com.




How Leveraging an Asia-Pacific Network Can Create Regional Efficiencies in Clinical Supply Management, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 17, 2017) - The session will examine how to leverage the major clinical supply centers of China, Singapore and Japan to support clinical trials within the Asia-Pacific region for both local and global study sponsors, with featured speaker Daniel Gao, Site Director of Catalent's Clinical Supply Services in Shanghai. There will be two live broadcasts on Tuesday, October 31, 2017, at 10am EDT (2pm GMT/UK) and on Wednesday November 1, 2017, at 10am CST, 7:30am IST (11am JST and 1pm AEDT).




Medigus Receives First Purchase Order From Izasa Hospital in Spain for Its MUSE System

Tue, 17 Oct 2017 07:00:00 EDT

OMER, ISRAEL--(Marketwired - Oct 17, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector, has provided an initial purchase order (PO) for the Medigus Ultrasonic Surgical Endostapler, or MUSET system. The PO covers the cost of a MUSET system console and endoscopic device, which will be available for use on patients suffering from gastroesophageal reflux disease (GERD).




The Alliance for Regenerative Medicine Releases Agenda for Fifth Annual 2017 European Advanced Therapies Investor Day

Tue, 17 Oct 2017 04:00:00 EDT

LONDON, UNITED KINGDOM and WASHINGTON, DC--(Marketwired - Oct 17, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies Investor Day, to be held November 9, 2017 in London.




Seventh Peer Reviewed Publication on Angle's Parsortix(TM) System

Tue, 17 Oct 2017 02:00:00 EDT

GUILDFORD, SURREY--(Marketwired - Oct 17, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)




Vendor Oversight: Five Best Practices in Optimizing Limited Resources

Mon, 16 Oct 2017 10:00:00 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - In an Xtalks clinical trials webinar upcoming on Wednesday, October 18, 2017 experts will share industry trends in optimizing internal resources, and five best practices to maximize productivity, manage time and budget, and achieve actionable, accurate clinical Intelligence when working with internal and external teams.




Athletes Free to Embrace CBD After WADA Decision - But There's a Catch -- CFN Media

Mon, 16 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 16, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the World Anti-Doping Agency's (WADA) recent decision to remove cannabidiol (CBD) from its list of banned substances in 2018, and that decision's ramifications for Medical Marijuana Inc.'s (OTC PINK: MJNA) subsidiary, HempMeds®.




The ALRT Diabetes Management System

Mon, 16 Oct 2017 08:30:00 EDT

Details of the patent pending diabetes management system featuring Predictive A1C and Insulin Dose Adjustment




Efficiently Managing Your Drug Supply Beyond IRT, New Webinar Hosted by Xtalks

Mon, 16 Oct 2017 08:22:47 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - In a complimentary webinar taking place on Monday, October 30, 2017 at 1 p.m. EDT, industry expert Brett Castano, Senior Architect of Project Management at endpoint Clinical, will examine how sponsors can manage their clinical trails more efficiently.




Specific Cardiovascular issues in Oncology Drug Development, New Webinar Hosted by Xtalks

Mon, 16 Oct 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - On October 24-25, 2017 scientific experts will be gathering at the CSRC/FDA Annual Meeting to discuss cardiac risk management and safety assessment in oncology drug development. BioTelemetry Research's Chief Medical Officer, Polina Voloshko, MD, and Vice President and Medical Director, Daniel Goodman, MD, will be attending. As a follow up to this meeting, Drs. Voloshko, and Goodman will be providing a complimentary webinar, broadcasting live on Wednesday, November 1, 2017 at 11:00am EDT, on the Key Takeaways from the upcoming CSRC/FDA Annual Meeting on Cardiac Safety and Cardiovascular Safety Issues in Oncology Drug Development.




Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

Mon, 16 Oct 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.




Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

Mon, 16 Oct 2017 07:00:00 EDT

Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions




Realm Therapeutics to Present at the 2017 BIO Investor Forum

Mon, 16 Oct 2017 02:00:00 EDT

MALVERN, PA--(Marketwired - Oct 16, 2017) - Realm Therapeutics PLC (AIM: RLM)




Monster Digital Announces Change to Date of Special Meeting and Extension of Offer to Amend and Exercise Warrants

Fri, 13 Oct 2017 09:00:00 EDT

SIMI VALLEY, CA--(Marketwired - Oct 13, 2017) - Monster Digital, Inc. ("Monster Digital" or "Monster") (NASDAQ: MSDI) announced today that it has changed the date of the Special Meeting of its Stockholders (the "Special Meeting") to Thursday November 9, 2017 at 10:00 am Pacific Time. The record date for determining those stockholders entitles to vote at the Special Meeting has not changed and will remain as the close of business on Wednesday, October 4, 2017. At the Special Meeting, Monster Digital stockholders will be asked to vote on the previously announced proposed combination of Monster Digital and Innovate Biopharmaceuticals, Inc. ("Innovate"), in addition to other matters.




Daily Diabetes Management in the Virtual World, New Webinar Hosted by Xtalks

Fri, 13 Oct 2017 08:13:42 EDT

TORONTO, ON--(Marketwired - October 13, 2017) - In a live broadcast upcoming on Tuesday, October 17, 2017 at 11am EDT (4pm BST.UK), guest speakers from PRA Health Sciences and Sanofi will provide insight into how they worked with patients with diabetes to gather information and how they used a Design Thinking Methodology approach for insight and prototype generation.




NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing

Fri, 13 Oct 2017 08:00:00 EDT

COSTA MESA, CA--(Marketwired - Oct 13, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced a further update to its news releases dated May 4, 2017 and July 11, 2017 with respect to the signing of a private placement with Schneider Finance LLC, an affiliate of Schneider Brothers Ltd, a global closed investment fund, for the sale of 1,000,000 shares of Series E Preferred Stock of the Company for gross proceeds of $20,000,000. As previously announced, SB Securities Ltd, an affiliate of Schneider Brothers Ltd, entered into a guaranty to the benefit of the Company that guarantees the payment of the $20,000,000 investment.




Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical

Fri, 13 Oct 2017 07:30:00 EDT

Non-Invasive Electroceutical Significantly Increased Cardiac Function and Reduced Ventricular Remodeling in Infarcted Animals